Metehan Berkkan,Cevat İlteriş Kıkılı,Bahadır Köylü et al.
Metehan Berkkan et al.
Alpelisib, a selective phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor, improves outcomes in hormone receptor-positive (HR+), HER2-negative, PIK3CA-mutated advanced breast cancer, but rare serious toxicities such as pneumonitis may o...
Dose dependent nanoparticle albumin bound paclitaxel + pembrolizumab alters the immune micro environment in a esophageal homograft mouse model [0.03%]
剂量依赖性的白蛋白结合型紫杉醇联合帕博利珠单抗在同种异体移植食道癌小鼠模型中改变免疫微环境
Gaofeng Liang,Hongyan Yu,Shengqian Wu et al.
Gaofeng Liang et al.
Esophageal cancer has remained a therapeutic challenge despite the advancements in targeted therapy and immunotherapy. This study investigated the mechanism by which neoadjuvant pembrolizumab combined with carboplatin and varying dosages of...
VEGF-A splicing variant in plasma is a predictive potential biomarker of bevacizumab in advanced non-squamous non-small cell lung cancer [0.03%]
贝伐单抗治疗非鳞状非小细胞肺癌的血浆预测生物标志物候选基因VEGF-A剪接变异体研究
Akira Matsui,Masahiro Morise,Ryosuke Kikuchi et al.
Akira Matsui et al.
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor-A (VEGF-A), a key mediator of tumor angiogenesis. Among VEGF-A splice variants, VEGF-Axxxa has proangiogenic activity, whereas VEGF-Axxxb exerts anti-angiogen...
A network between infectious diseases department and general practitioners for COVID-19 patients: towards a strengthened link? [0.03%]
传染病部门与全科医师之间的新冠肺炎患者转诊网络：加强联系？
S Dettori,C Dentone,G Averame et al.
S Dettori et al.
General practitioners (GPs) play a crucial role in primary care, particularly during the COVID-19 pandemic, collaborating with Infectious Diseases (ID) specialists. After a training period, a selected group of GPs were able to prospectively...
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study [0.03%]
土耳其肿瘤学研究小组多中心研究：靶向治疗转移性肺鳞癌疗效分析
Bilgeşah Kılıçtaş,Murat Araz,Ahmet Oruç et al.
Bilgeşah Kılıçtaş et al.
This multicentre real-world study evaluated the efficacy of targeted therapies in Turkish patients with metastatic squamous cell lung carcinoma harbouring driver mutations. Sixty-four patients with alterations such as EGFR, ALK, and ROS1 wh...
Successful remdesivir treatment of coronavirus OC43 pneumonia in a lung transplant recipient [0.03%]
成功利用瑞德西韦治疗一名肺移植受者患上的冠状病毒OC43肺炎
Raffaella Gallo,Lorenzo Bertolino,Fabian Patauner et al.
Raffaella Gallo et al.
Lung transplantation is a well-established treatment for end-stage lung disease. Viral infections represent major infective complications after lung transplantation. Respiratory viruses can increase immune responses and the development of a...
Efficacy and safety of trastuzumab deruxtecan in HER2-high and HER2-low breast cancer: a systematic review and meta-analysis of randomized controlled trials [0.03%]
抗HER2高表达及低表达阳性晚期乳腺癌疗效与安全性：德喜曲妥珠单抗的系统评价和网状Meta分析
Sheng-Yen Hsiao,Wei-Ting Lin,Cheng-Yao Lin et al.
Sheng-Yen Hsiao et al.
Breast cancer is the most common malignancy, with approximately ∼20% of cases involving HER2 overexpression. Trastuzumab deruxtecan (T-DXd), an HER2-targeted antibody-drug conjugate, is approved for HER2-high and HER2-low disease. This met...
Novel SNX25-ROS1 fusion mutation confers therapeutic sensitivity to entrectinib: a case report and literature review [0.03%]
新型SNX25-ROS1融合突变对恩曲替尼敏感性病例报道及文献复习
Qian Liu,Mingqin Wei,Youhong Dong et al.
Qian Liu et al.
ROS1 gene fusions are oncogenic driver in 1-2% non-small cell lung cancer (NSCLC). This report presents the first case of a novel SNX25-ROS1 fusion mutation in a 56-year-old female with lung adenocacinoma, presenting with headaches and beha...
USP54 suppresses bladder cancer proliferation, stemness, and cisplatin resistance via deubiquitination-mediated stabilization of SIRT6 [0.03%]
去泛素化介导的SIRT6稳定化抑制USP54膀胱癌增殖，肿瘤干细胞特性及顺铂耐药性
Yinan Han,Shengxing Wang,Rurui Xia et al.
Yinan Han et al.
Bladder cancer is a prevalent and lethal malignancy worldwide, with treatment options often limited by the development of chemoresistance, especially to cisplatin-based regimens. In this study, we identified ubiquitin-specific protease 54 (...
Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis [0.03%]
瑞戈非尼治疗成人复发胶质母细胞瘤的单臂meta分析研究
Marcos Henrique da Silva Mezzari,Natan Lucca Lima,Bárbara Ghizoni Maggi et al.
Marcos Henrique da Silva Mezzari et al.
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted throug...